Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287985 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of VIS649 for IgA Nephropathy
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT04287985 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 155 participants.
The verdict
NCT04287985, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Interventions
- DRUG Dose-Placebo
- DRUG Low Dose-VIS649
- DRUG Medium Dose-VIS649
- DRUG High Dose-VIS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04287985
The ClinicalTrials.gov registry entry for NCT04287985 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dose-Placebo is the first listed.
NCT04287985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04287985 about?
NCT04287985 is a clinical study titled "Safety and Efficacy Study of VIS649 for IgA Nephropathy". The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
What is the current status of trial NCT04287985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2020-07-20. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT04287985?
The interventions under investigation include: Dose-Placebo (DRUG), Low Dose-VIS649 (DRUG), Medium Dose-VIS649 (DRUG), High Dose-VIS649 (DRUG).
Who is sponsoring clinical trial NCT04287985?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.